PVSRIPO for Patients With Unresectable Melanoma

Inclusion Criteria:

Undergone prior vaccination against PV and received a boost immunization with trivalent IPOL® (Sanofi-Pasteur SA) at least 1 week, but less than 6 weeks, prior to administration of PVSRIPO (within 6 months of PVSRIPO retreatment).

a. Note: Patients who are unsure of their prior vaccination status/who have not been vaccinated must provide proof of vaccination and/or evidence of anti-PV immunity prior to enrollment, as applicable.

The patient must have received a boost immunization with trivalent inactivated IPOLâ„¢ (Sanofi-Pasteur) at least 1 week prior to administration of the study agent.
Patient must have histologically proven unresectable, recurrent, melanoma, stage IIIB, IIIC, or stage IV (AJCC staging must be documented in patient's medical record, as determined by CT of the chest, abdomen and pelvis, and/or whole body PET scan, and MRI of the brain within 4 weeks prior to administration of study drug).
Patients with BRAF mutations, must have failed at least 2 lines of therapy, specifically one BRAF targeted therapy and at least one anti-PD-1 based therapy. For BRAF wild type, patients must have failed at least one anti-PD-1 based therapy.
Patient must be ≥ 18 years of age.
Patient must have an ECOG/Zubrod status of 0-1.
Patient's disease must be bi-dimensionally measurable by caliper or radiological method as defined in the irRC criteria.

At least 1 injectable cutaneous, subcutaneous or nodal melanoma lesion ≥ 10 mm in longest diameter or, multiple injectable melanoma lesions which in aggregate have a longest diameter of ≥ 10 mm (Cohorts 0 and possibly 1). For cohorts where 2 or 3 injections are planned (Cohorts 1 and 2), the patient must have at least 2 injectable melanoma lesions (when 2 doses are planned) or ≥3 injectable melanoma lesions when at least 3 doses are planned in different lesions (Cohorts 2 through 4).

a. Note: PVSRIPO retreatment requires ≥2 lesions amenable to injection.

At least one measurable lesion that will not be injected.
Serum lactate dehydrogenase (LDH) levels less than 1.5 x upper limit of normal (ULN).

Patient must have adequate bone marrow, liver and renal function as assessed by the following:

Hemoglobin > 9.0 g/dl
White blood count (WBC) of > 2000 m3
Absolute neutrophil count (ANC) > 1,000/mm3
Platelet count > 75,000/mm3
Total bilirubin < 2.0 x ULN
ALT and AST < 2.5 x the ULN

Exclusion Criteria:

Females who are pregnant or breast-feeding.
Adults of reproductive potential not employing an effective method of birth control.

Patients with severe, active co-morbidity, defined as follows:

Patients with an active infection requiring treatment or having an unexplained febrile illness (Tmax > 99.5°F/37.5°C).
Patients with impaired cardiac function or clinically significant cardiac disease, such as congestive heart failure requiring treatment (New York Heart Association Class ≥ 2), uncontrolled hypertension or clinically significant arrhythmia; QTcF > 470 msec on ECG if performed or congenital long QT syndrome; acute myocardial infarction or unstable angina pectoris < 3 months prior to study.
Patients with known lung (FEV1 < 50%) disease or uncontrolled diabetes mellitus (HgbA1c>7).
Patients with albumin allergy.
Autoimmune disease: History of or current active autoimmune diseases, [e.g. including but not limited to inflammatory bowel diseases [IBD], rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (such as Guillain-Barre syndrome)]. Vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are not exclusionary.
Known immunosuppressive disease, human immunodeficiency virus (HIV) infection, or chronic Hepatitis B or C.
Patients with a previous history of neurological complications due to PV infection.
Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy. Guidelines for this recovery period are dependent upon the specific therapeutic agent being used. Toxicities must have resolved to CTCAE grade 1 or less with the following exceptions (alopecia, fatigue, vitiligo).
Patients with undetectable anti-tetanus toxoid IgG.
Patients with known history of agammaglobulinemia.
Patients on greater than 10 mg per day of prednisone within the 2 weeks prior to admission for PVSRIPO injection.
Patients with worsening steroid myopathy (history of gradual progression of bilateral proximal muscle weakness, and atrophy of proximal muscle groups).
Patients with prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin.
Clinically active cerebral or bone metastases.
Greater than 3 visceral metastases (this does not include nodal metastases associated with visceral organs).
Prior allogeneic stem cell transplantation.
Concomitant therapy with any of the following: IL-2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses). However, during the course of the study, use of corticosteroids is allowed if used for treating irAEs, adrenal insufficiencies, or if administered at doses of prednisone 10 mg daily or equivalent.
Active clinically serious infection > CTCAE Grade 2.
Antineoplastic therapy, radiotherapy, or any other investigational drug within 15 days prior to first study drug administration.